Niche regulatory focus Pharmakey specializes in IND, NDA, ANDA, MAA, BLA and 505(b)(2) eCTD publishing and submissions, presenting a targeted opportunity to upsell regulatory publishing services to small to mid-sized pharma developers navigating complex submissions.

Experienced consultants Most consultants boast at least 20 years of drug development and regulatory experience, enabling Pharmakey to position high-value, expert advisory services for early-stage and growth-stage companies seeking credible, end-to-end support.

Global quality promise All publishing staff are U.S. citizens and the firm reports a flawless track record with no technical rejections, which can be leveraged to build trust with risk-averse clients requiring reliable regulatory submissions.

Proof of capability In-house eCTD publishing capabilities using Lorenz system, document and submission quality control, and experience across diverse dosage forms open cross-selling avenues to clients expanding portfolios to tablets, topicals, inhalation, and parenterals.

Growth through partnerships With revenue under $1M and a boutique size, Pharmakey is well-positioned to partner with larger CROs or mid-sized firms for collaborative outsourcing, white-label publishing, or tiered consulting engagements to scale revenue quickly.